AU · rank #14 · 2026-09-07
DSFIR
AMSTERDAM · EUR · $26.57B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.898 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.08 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 12 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $93.67 | +0.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +25.50% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.2% |
| 52w high | $96.74 |
| Market cap (USD) | $26.57B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich is a specialty ingredients and solutions company serving food, nutrition, health and beauty markets through three focused business units following the divestiture of its Animal Nutrition & Health segment to CVC.
Rationale
100% revision agreement across 19 analysts, a 65.6% consensus upside, and accelerating EPS upgrades over 30/60/90-day windows are directly reinforced by Q2 2026's 6% LFL growth beat, 12% share-price surge, and management's upgrade to the upper end of full-year guidance—classic conditions for the analyst_upside signal to have real fundamental backing rather than mere sentiment drift.
Material risks
- 1Vitamins and commodity nutritional ingredients face structural commoditization from lower-cost Asian producers, and with ANH divested the remaining portfolio's margin trajectory to ~22–23% by 2028 depends heavily on DSM-Firmenich sustaining pricing power in segments where differentiation is contested—a failure here directly breaks the synergy and margin expansion thesis underpinning analyst targets.
- 2The 42% analyst target price dispersion is unusually wide for a €26.6B large-cap, signaling deep disagreement on terminal margin and synergy delivery; if the 2026–2027 synergy ramp (€300–350M toward €500M) disappoints, the high-upside targets anchoring the signal will compress rapidly and consensus will reverse.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.